Iconoclast,

This GLP1-R agonists and SGLT2 inhibitor stuff is all old news. Even before Ozempic (injectable semaglutide), another GLP-1R agonist Victoza (injectable liraglutide) had already had a CVD reduction label. Regulatory agencies (i.e. FDA, EMA), medical societies (i.e. ACC, ESC, ADA, EASD), cardiologists/endocrinologists, analysts and other companies in this area were already fully aware of the proven cardio risk reduction by these two classes of drugs. 

Did the success of SGLT2 inhibitors stop the GLP1R agonists from being developed and approved? No. Did the success of GLP1R agonists stop SGLT2 inhibitors from being developed and approved? No. 

Keep in mind that on top of SGLT2 inhibitors in BETonMACE, apabetalone elicited a >50% RRR. There weren't very many BETonMACE patients on GLP1R agonists in BETonMACE, but also possible that apabetalone elicited MACE reduction in top of GLP1R agonists.

Standard of care evolves. But there is always residual risk. Apabetalone acts via an entirety different mechanism of action and based on BETonMACE findings elicited robust MACE reduction on top of standard of care. Unfortunately, underpowered study.

BDAZ